Xu Cong Claire (NBP) details options, RSUs and share stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
NovaBridge Biosciences executive Xu Cong Claire filed an initial ownership report detailing current equity interests in the company. The filing lists several employee share options over Ordinary Shares granted between 2021 and 2024 at exercise prices ranging from $60.7000 to $1.0500, with expirations extending to 2034. It also discloses restricted share units that each represent a right to receive one American Depositary Share, and a direct holding of 288,266 Ordinary Shares. The derivative awards include both fully vested options and grants that vest over time according to specified multi‑year schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Xu Cong Claire
Role
See remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | 2021 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2022 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2023 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2024 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2024 Employee Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
2021 Employee Share Option (right to buy) — 22,900 shares (Direct);
2022 Employee Share Option (right to buy) — 43,690 shares (Direct);
2023 Employee Share Option (right to buy) — 57,660 shares (Direct);
2024 Employee Share Option (right to buy) — 146,865 shares (Direct);
Restricted Share Units — 36,716 shares (Direct);
Ordinary Shares — 288,266 shares (Direct)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Reported securities are represented by 123,594 ADSs. Number of underlying securities and exercise price expressed in terms of ADSs. The option was granted on July 21, 2021 and is fully vested and exercisable. The option was granted on March 4, 2022 and is fully vested and exercisable. The option was granted on January 4, 2023. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option to purchase 195,820 ADSs was granted on May 30, 2024. The option vested or shall vest and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Amount of underlying securities excludes a portion of the option that has vested and been exercised. The option was granted on September 3, 2024 and is fully vested and exercisable. Amount of underlying securities excludes a portion of the option that has vested and been exercised. On May 30, 2024, the Reporting Person was granted 65,270 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. On January 4, 2023, the Reporting Person was granted 21,620 RSUs. The RSUs vested or shall vest in four equal annual installments beginning on the first anniversary of the grant date.
FAQ
What does the NovaBridge Biosciences (NBP) Form 3 filing show for Xu Cong Claire?
The Form 3 shows Xu Cong Claire’s existing equity interests in NovaBridge Biosciences, including multiple employee share options, restricted share units tied to ADSs, and 288,266 directly held Ordinary Shares, establishing a baseline of insider ownership at the time of becoming a reporting person.
What stock options does Xu Cong Claire hold in NovaBridge Biosciences (NBP)?
Xu Cong Claire holds several employee share options over Ordinary Shares from 2021, 2022, 2023 and 2024 grants, with exercise prices from $60.7000 down to $1.0500 and expirations through 2034, reflecting both fully vested and time‑vested option awards.
Does the NovaBridge Biosciences (NBP) Form 3 indicate any recent insider buying or selling?
No specific buy or sell transactions are identified. The entries are categorized as holdings with unknown transaction codes, indicating the Form 3 serves to disclose existing options, RSUs and share ownership rather than report new market purchases or sales.
What portion of Xu Cong Claire’s NovaBridge (NBP) options are already exercisable?
Footnotes clarify that the 2021 and 2022 options, and a 2024 September 3, 2024 grant, are fully vested and exercisable. Other 2023 and 2024 option and RSU grants vest over multi‑year schedules starting on their first anniversaries, creating a mix of vested and unvested interests.